OMER Earnings Prediction
The chart below shows how OMER performed 10 days before and after its earnings report, based on data from the past quarters. Typically, OMER sees a +0.03% change in stock price 10 days leading up to the earnings, and a -2.00% change 10 days following the report. On the earnings day itself, the stock moves by -3.51%. This data can give you a slight idea of what to expect for the next quarter's release.
OMER Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.56
-6.67%
-42.27%
No Data Available
OMER Earnings Analysis
Omeros Corporation Corporation (OMER.O) Earnings Conference Call
Positive
Quarterly Net Loss Comparison: The net loss for the third quarter of 2024 was $32.2 million or $0.56 per share compared to a net loss of $56 million or $0.97 per share in the second quarter of this year.
Cash and Investments Decline: As of September 30, 2024, we had $123.2 million of cash and investments on hand, a decrease of $35.8 million from June 30, 2024.
Cost Reduction in Q3: Cost and expenses from continuing operations for the third quarter were $35.4 million which was a decrease of $23.8 million from the second quarter of this year.
R&D Expense Impact: The decrease was primarily driven by $17.6 million of R&D expense related to the manufacture of narsoplimab drug substance that commenced in October 2023, and which were delivered and expensed in the second quarter of this year.
Omidria Sales and Royalties: Omidria royalty ties for the third quarter were $9.3 million and Omidria net sales of $31 million.
Negative
Quarterly Net Loss Comparison: Our net loss for the third quarter of 2024 was $32.2 million or $0.56 per share compared to a net loss of $56 million or $0.97 per share in the second quarter of this year.
Net Loss Decrease Analysis: The $23.8 million quarter-over-quarter decrease in the net loss was primarily driven by $17.6 million of R&D expense related to the manufacture of narsoplimab drug substance recorded as an expense in the second quarter of this year.
Cash and Investments Decline: As of September 30, 2024, we had $123.2 million of cash and investments on hand, a decrease of $35.8 million from June 30, 2024.
Cost Reduction in Q3: Cost and expenses from continuing operations for the third quarter were $35.4 million which was a decrease of $23.8 million from the second quarter of this year.
Interest Expense Decrease: Interest expense for the third quarter was $4.1 million which was $5.2 million lower than the second quarter of this year.
OMER FAQs
How does OMER typically perform around its earnings report dates?
Is Omeros Corporation (OMER) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
OMER Earning Call Sentiment
Omeros Corporation (OMER) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
OMER.O
-2.39%Positive
The earnings call presents a mixed picture: while there are positive elements such as debt reduction and ongoing clinical developments, there are concerns over liquidity, regulatory risks, and competitive pressures. The Q&A section reveals cautious optimism, but management's unclear responses on certain topics may raise doubts. The decrease in net loss is a positive sign, yet cash reserves have diminished significantly. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
